The use of fixed ratio combination of insulin glargine and lixisenatide in patients with type 2 diabetes mellitus in real clinical practice. Own clinical experience
- Authors: Khamnueva L.Y.1, Andreeva L.S1, Davydova A.V1, Chugunova E.V1, Tokareva N.P2, Molodtsova N.Y.1
-
Affiliations:
- Irkutsk State Medical University
- Irkutsk Regional Clinical Hospital
- Issue: Vol 27, No 12 (2020)
- Pages: 107-111
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312928
- DOI: https://doi.org/10.18565/pharmateca.2020.12.107-111
- ID: 312928
Cite item
Open Access
Access granted
Abstract
Background. The last 20 years of the development of diabetology have been marked by the emergence of many new pharmacotherapeutio options for the management of type 2 diabetes. One promising and effective therapeutic approach is a fixed ratio combination of basal insulin and a GLP-1 receptor agonist. Since 2018, fixed ratio combination of basal insulin glargine 100 U/ml and prandial GLP-1 RA lixisenatide has been available in Russia. As shown by the LixiLan-O clinical study, as well as its subanalysis in patients with a baseline HbA1c level of more than 9%, a fixed combination of insulin glargine and lixisenatide allows 74% of patients who have not previously achieved treatment goals with the use of oral antihyperglycemic drugs to achieve HbA1c less than 7%. Description of the clinical case. This publication presents two clinical cases of successful initiation of insulin therapy with a fixed ratio combination of glargine and lixisenatide in patients with type 2 diabetes with a baseline HbA1c level above 9% who did not reach the target glycemic values when using a combination of oral antihyperglycemic drugs. Conclusion. Comparison and analysis of published data from randomized trials and case studies in real-life clinical practice is essential. The efficacy and safety parameters of the fixed ratio combination of insulin glargine and lixisenatide observed in the cases reviewed correlate with those shown in the LixiLan-O randomized clinical trial.
Full Text
About the authors
Larisa Yu. Khamnueva
Irkutsk State Medical University
Email: hamnueval@mail.ru
Dr. Sci. (Med.), Professor, Head of the Department of Endocrinology, Clinical Pharmacology and Immunology 1, Krasny Vosstaniya str., Irkutsk 664003, Russian Federation
L. S Andreeva
Irkutsk State Medical UniversityIrkutsk, Russia
A. V Davydova
Irkutsk State Medical UniversityIrkutsk, Russia
E. V Chugunova
Irkutsk State Medical UniversityIrkutsk, Russia
N. P Tokareva
Irkutsk Regional Clinical HospitalIrkutsk, Russia
N. Yu Molodtsova
Irkutsk State Medical UniversityIrkutsk, Russia
References
- Larsson H., Ahrén B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diab Care 2000;23(5):650-57. doi: 10.2337/diacare.23.5.650.
- Dunning B.E., Foley J., Ahrén B. Alpha-cell function in health and disease: influence of GLP-1. Diabetol. 2005;48(9):1700-713. doi: 10.1007/s00125-005-1878-0.
- Reaven G.M., Chen Y.D., Golay A., et al. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulindependent diabetes mellitus. J Clin Endocrinol Metab. 1987;64(1):106-110. doi: 10.1210/jcem-64-1-106.
- Ahrn B. Beta- and alpha-cell dysfunction in subjects developing impaired glucose tolerance: outcome of a 12-year prospective study in postmenopausal Caucasian women. Diab. 2009;58(3):726-31. doi: 10.2337/db08-1158.
- UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
- Buteau J. GLP-1 signaling and the regulation of pancreatic-cells mass/function. Avanc Diab. 2015;31(3):3-8. doi: 10.1016/S1134-3230(11)70002-3
- Davies M.J., DAlessio D.A., Fradkin J., et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diab Care 2018;41(12):2669-71. doi: 10.2337/dci18-0033.
- Blonde L., Anderson J.E., Chava P., Dendy J.A. Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes. Curr Med Res Opin. 2019;35(5):793-804. doi: 10.1080/03007995.2018.1541790.
- Алгоритмы специализированной медицинской помощи больным сахарным диабетом. 9-й выпуск, доп. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. М., 2019. С. 38-46.
- Инструкция по медицинскому применению лекарственного препарата Соликва СолоСтар®, ЛП-004874-100620.
- Rosenstock J., Aronson R., Grunberger G., et al. Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial. Diab Care 2016;39(11):2026-35. doi: 10.2337/dc16-0917.
- Davies M.J., Russell-Jones D., Barber T.M., et al. Glycaemic benefit of iGlarLixi in insulin-naive type 2 diabetes patients with high HbA1c or those with inadequate glycaemic control on two oral antihyperglycaemic drugs in the LixiLan-O randomized trial. Diab Obes Metab. 2019;21(8):1967-72. doi: 10.1111/dom.13791.
- Bonora E., Corrao G., Bagnardi V., et al. Prevalence and correlates of post-prandial hyperglycaemia in a large sample of patients with type 2 diabetes mellitus. Diabetol. 2006;49(5):846-54. Doi: 10.1007/ s00125-006-0203-x.
- Erlinger T.P., Brancati F.L. Postchallenge hyperglycemia in a national sample of U.S. adults with type 2 diabetes. Diab Care 2001;24(10):1734-38. doi: 10.2337/diacare.24.10.1734.
- Monnier L., Colette C., Dunseath G.J., Owens D.R. The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diab Care 2007;30(2):263-69. doi: 10.2337/dc06-1612.
- Peyrot M., Rubin R.R., Kruger D.F. Correlates of insulin injection omission. Diab Care 2010;33(2):240-45. doi: 10.2337/dc09-1348.
- Sarbacker G.B., Urteaga E.M. Adherence to insulin therapy Diab Spectr. 2016;29(3):166-70. doi: 10.2337/diaspect.29.3.166.
Supplementary files
